MedPath

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Phase 1
Conditions
Irritability Associated With Autism Spectrum Disorder
Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Registration Number
EUCTR2018-004899-35-Outside-EU/EEA
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
A
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

5 to 17 year of age or turned 18 while enrolled in the 331-201-00148 study
Autism Spectrum Disorder
Completion of 331-201-00148 trial
Investigator assessment

Are the trial subjects under 18? yes
Number of subjects for this age range: 95
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 1
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

Did not complete treatment period or incurred significant protocol deviations during 331-201-00148 study
Sexually active males or female of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose
Female with positive pregnancy test

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath